News
-
Vivaldi Biosciences announced that the Flu Lab has provided a grant to fund a transmission study of the company’s DeltaFLU intranasal universal influenza vaccine. According to the company, the study will evaluate the ability of… Read more . . .
-
After recently receiving authorization for a Phase 1 trial of its ETH47 mRNA therapy, Ethris has initiated the study, the company announced. The trial is expected to enroll 88 healthy participants aged 18 to 55… Read more . . .
-
The 34th iteration of the Drug Delivery to the Lungs (DDL) Conference, DDL 2023, drew approximately 930 OINDP specialists to the Edinburgh International Conference Centre (EICC) December 6 – 8, with more than 100 additional… Read more . . .
-
Marinomed Biotech announced that DKSH subsidiary Favorex has acquired commercialization rights to Marinomed’s Carragelose iota-carrageenan nasal spray for Thailand, Malaysia, Myanmar, and the Philippines. Earlier this year, Carragelose nasal spray was approved in Mexico, where… Read more . . .
-
Agomab Therapeutics announced that it has initiated a Phase 1 trial of its AGMB-447 inhaled ALK5 inhibitor that is expected to enroll 76 healthy subjects and idiopathic pulmonary fibrosis (IPF) patients. According to Agomab, the… Read more . . .
-
Irish start-up MDI Plus has announced the availability of its novel metered dose inhaler carton, which can be used as a spacer. The carton/spacer includes holes in each end of the cardboard box, with an… Read more . . .
-
CRO Oz-UK has announced that it is installing a new manufacturing line for metered dose inhalers that use LGWP propellants and expects the new line to be in operation by July 2024. According to the… Read more . . .
-
Aptar Pharma has announced the official opening of its new 7,000 sq m manufacturing facility in Mumbai, India. Aptar has been manufacturing MDI valves and pumps at the site since 2012. According to Aptar, the… Read more . . .
-
The FDA has extended the review period for Optinose’s sNDA seeking approval of Xhance fluticasone propionate nasal spray for the treatment of chronic sinusitis in patients without nasal polyps, Optinose said. Xhance was originally approved… Read more . . .
-
CDMO Recipharm announced that it has hired former Koura Global Business Development Director Simon Gardner as Business Development Specialist for pMDIs to assist customers with the transition to LGWP propellants. Recipharm President, Advanced Delivery Systems, Chris Hirst… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.